

# Sattva S Neelapu

List of Publications by Year  
in descending order

Source: <https://exaly.com/author-pdf/7681690/publications.pdf>

Version: 2024-02-01

175  
papers

23,804  
citations

17440  
63  
h-index

8396  
147  
g-index

179  
all docs

179  
docs citations

179  
times ranked

19891  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	3.5	43
2	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2022, 22, 85-96.	22.7	315
3	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. <i>Cancer Drug Discovery and Development</i> , 2022, , 207-219.	0.4	1
4	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2867-2871.	5.2	24
5	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 91-103.	10.7	236
6	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 1143-1151.	5.2	21
7	SIRPÎ±+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. <i>Blood Advances</i> , 2022, 6, 3286-3293.	5.2	3
8	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2757-2762.	5.2	19
9	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	30.7	114
10	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
11	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. <i>Nature Communications</i> , 2022, 13, 2228.	12.8	14
12	Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. <i>Blood</i> , 2022, 140, 504-515.	1.4	19
13	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	5.0	29
14	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 753-759.	0.4	6
15	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. <i>Blood</i> , 2022, 140, 851-860.	1.4	28
16	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2667-2672.	3.5	92
17	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. <i>Blood</i> , 2021, 137, 1832-1835.	1.4	48
18	Chimeric antigen receptor Tâ€cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	2.4	19

#	ARTICLE	IF	CITATIONS
19	Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. <i>Haematologica</i> , 2021, 106, 1504-1506.	3.5	14
20	Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T-cell therapy: A case report and brief review of the literature. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e104.	0.9	1
21	Safety of CAR T-cell therapy in kidney transplant recipients. <i>Blood</i> , 2021, 137, 2558-2562.	1.4	33
22	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. <i>Blood</i> , 2021, 137, 1124-1129.	1.4	7
23	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 456-466.	1.6	21
24	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
25	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3272-3276.	1.4	95
26	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	2.8	19
27	CAR-T failure: beyond antigen loss and T cells. <i>Blood</i> , 2021, 137, 2567-2568.	1.4	12
28	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood</i> , 2021, 138, 1081-1085.	1.4	84
29	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. <i>Cancers</i> , 2021, 13, 2782.	3.7	21
30	Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 930.e1-930.e10.	1.2	24
31	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	5.2	57
32	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	5.2	42
33	Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. <i>International Journal of Infectious Diseases</i> , 2021, 112, 327-329.	3.3	8
34	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151216.	1.5	13
35	COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT. <i>Korean Journal of Radiology</i> , 2021, 22, 1938.	3.4	17
36	Long-Term (4 Year and 5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 1764-1764.	1.4	48

#	ARTICLE	IF	CITATIONS
37	Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. JAMA Oncology, 2020, 6, 281.	7.1	36
38	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	5.2	238
39	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887.	30.7	321
40	Editorial: CAR T-Cell Therapies in Hematologic Tumors. Frontiers in Oncology, 2020, 10, 588134.	2.8	2
41	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951.	5.2	69
42	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2020, 38, 3119-3128.	1.6	481
43	Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. British Journal of Haematology, 2020, 190, e114-e117.	2.5	5
44	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883.	5.2	134
45	Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Advances, 2020, 4, 3123-3127.	5.2	115
46	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia and Lymphoma, 2020, 61, 1380-1387.	1.3	4
47	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discovery, 2020, 10, 440-459.	9.4	103
48	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	27.0	1,252
49	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica, 2020, 105, 1907-1913.	3.5	23
50	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<sc>MCL</sc>) -outcomes and mutation profile from venetoclax resistant <sc>MCL</sc> patients. American Journal of Hematology, 2020, 95, 623-629.	4.1	54
51	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	2.2	31
52	Not So FAST: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction. Cancer Discovery, 2020, 10, 492-494.	9.4	3
53	A CAR against CAR for unintended consequences. Blood, 2020, 135, 460-462.	1.4	0
54	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	5.2	43

#	ARTICLE	IF	CITATIONS
55	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
56	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
57	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 2020, 135, 2106-2109.	1.4	90
58	Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel. Blood, 2020, 136, 16-17.	1.4	3
59	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	27.6	178
60	Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. British Journal of Haematology, 2019, 185, 334-338.	2.5	16
61	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
62	Reply. Biology of Blood and Marrow Transplantation, 2019, 25, e211-e212.	2.0	1
63	Managing the toxicities of CAR T-cell therapy. Hematological Oncology, 2019, 37, 48-52.	1.7	214
64	Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. , 2019, 7, 126.		17
65	Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood, 2019, 133, 2800-2802.	1.4	49
66	CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia, 2019, 33, 2640-2653.	7.2	40
67	CAR-T efficacy: is conditioning the key?. Blood, 2019, 133, 1799-1800.	1.4	79
68	Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Current Oncology Reports, 2019, 21, 38.	4.0	20
69	Frontline antibiotic therapy for early-stage Helicobacter pylori -negative gastric MALT lymphoma. American Journal of Hematology, 2019, 94, E150-E153.	4.1	7
70	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Advances, 2019, 3, 2400-2408.	5.2	28
71	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 789-796.	1.3	12
72	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741

#	ARTICLE	IF	CITATIONS
73	Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Annals of Hematology, 2019, 98, 1169-1176.	1.8	11
74	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€² trial. Lancet Oncology, The, 2019, 20, 31-42.	10.7	1,467
75	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61.	0.4	7
76	Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood, 2019, 134, 765-765.	1.4	23
77	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. Blood, 2019, 134, 203-203.	1.4	48
78	Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Blood, 2019, 134, 1583-1583.	1.4	3
79	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	27.6	114
80	CAR T-Cell Therapy in Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1065-1065.	27.0	53
81	Chimeric antigen receptor T-cell therapy â€” assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	27.6	1,659
82	Positron emission tomographyâ€”computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Advances, 2018, 2, 1334-1343.	5.2	23
83	Longâ€”term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	2.5	81
84	The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Practice and Research in Clinical Haematology, 2018, 31, 293-298.	1.7	44
85	Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer, 2018, 18, 187.	2.6	16
86	Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study. Blood, 2018, 132, 447-447.	1.4	3
87	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	1.4	81
88	Targeting CAR T Resistance Due to CD19 Loss with CD79b-Specific CAR T Cells in B-Cell Malignancies. Blood, 2018, 132, 1662-1662.	1.4	2
89	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 2017, 25, 285-295.	8.2	498
90	Chimeric Antigen Receptor T Cells in Hematologic Malignancies. Pharmacotherapy, 2017, 37, 334-345.	2.6	52

#	ARTICLE	IF	CITATIONS
91	Clinical and pathological characteristics of HIV- and HHV-8â€“negative Castleman disease. <i>Blood</i> , 2017, 129, 1658-1668.	1.4	127
92	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 100-111.	10.7	296
93	Encouraging activity for R-CHOP in advanced stage nodular lymphocyteâ€“predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	1.4	65
94	Ultraâ€“lowâ€“dose radiotherapy for definitive management of ocular adnexal Bâ€“cell lymphoma. <i>Head and Neck</i> , 2017, 39, 1095-1100.	2.0	87
95	High tenâ€“year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (Râ€“scp>FND</scp>) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017, 177, 263-270.	2.5	14
96	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. <i>Haematologica</i> , 2017, 102, 373-380.	3.5	58
97	3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. <i>Lab on A Chip</i> , 2017, 17, 407-414.	6.0	60
98	The survival outcome of patients with relapsed/refractory peripheral Tâ€“cell lymphomaâ€“not otherwise specified and angioimmunoblastic Tâ€“cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 750-758.	2.5	78
99	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	1.4	1,084
100	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
101	Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19). , 2017, , .		5
102	Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 622-631.	10.7	149
103	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	3.5	75
104	IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. <i>Oncolmmunology</i> , 2016, 5, e1237327.	4.6	17
105	Management strategies and outcomes for very elderly patients with diffuse large Bâ€“cell lymphoma. <i>Cancer</i> , 2016, 122, 3145-3151.	4.1	61
106	Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells. <i>Oncolmmunology</i> , 2016, 5, e1232220.	4.6	5
107	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. <i>Science Signaling</i> , 2016, 9, ra17.	3.6	147
108	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2016, 128, 5628-5628.	1.4	3



#	ARTICLE	IF	CITATIONS
109	Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. Blood, 2016, 128, 59-59.	1.4	47
110	Targeting Wnt pathway in mantle cell lymphoma-initiating cells. Journal of Hematology and Oncology, 2015, 8, 63.	17.0	43
111	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology, 2015, 171, 726-735.	2.5	50
112	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	2.5	81
113	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Current Opinion in Oncology, 2015, 27, 384-391.	2.4	18
114	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. Current Oncology Reports, 2015, 17, 30.	4.0	9
115	Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood, 2015, 125, 3357-3359.	1.4	87
116	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molecular Oncology, 2015, 9, 2043-2053.	4.6	87
117	Targeting the tumor niche to treat cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12907-12908.	7.1	3
118	Anti-PD-1 antibodies for the treatment of B-cell lymphoma. Oncoimmunology, 2014, 3, e28101.	4.6	5
119	Induction of p53-mediated transcription and apoptosis by exportin1 inhibition in mantle cell lymphoma. Cancer Science, 2014, 105, 795-801.	3.9	81
120	Rush Hour Traffic: Directing T Cells to Tumor. Journal of the National Cancer Institute, 2014, 106, dju301-dju301.	6.3	0
121	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 69-77.	10.7	518
122	The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British Journal of Haematology, 2014, 165, 112-116.	2.5	50
123	Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature, 2014, 507, 513-518.	27.8	303
124	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1311-1318.	10.7	239
125	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. British Journal of Haematology, 2014, 166, 891-901.	2.5	310
126	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. International Journal of Cancer, 2014, 135, 2834-2846.	5.1	31



#	ARTICLE	IF	CITATIONS
127	SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. <i>Blood</i> , 2014, 124, 1629-1629.	1.4	5
128	Detection of circulating tumour <scp>DNA</scp> in patients with aggressive Bâ€cell nonâ€Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 123-126.	2.5	67
129	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. <i>Haematologica</i> , 2013, 98, 1458-1466.	3.5	58
130	Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2013, 190, 6681-6693.	0.8	77
131	Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen. <i>Journal of Immunology</i> , 2013, 190, 4887-4898.	0.8	45
132	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6882-6890.	7.0	103
133	Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). <i>Blood</i> , 2013, 122, 3028-3028.	1.4	0
134	Therapy of newly diagnosed follicular lymphoma. <i>Frontiers in Oncology</i> , 2012, 2, 188.	2.8	0
135	Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4161-4167.	1.6	137
136	Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i> , 2012, 119, 6373-6378.	1.4	97
137	Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. <i>Blood</i> , 2012, 119, 161-169.	1.4	103
138	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology</i> , The, 2012, 13, 716-723.	10.7	274
139	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782.	1.6	162
140	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4123-4128.	1.4	70
141	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. <i>Haematologica</i> , 2012, 97, 586-594.	3.5	110
142	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	10.7	168
143	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	1.6	230
144	Targeting Human B-cell Malignancies through Ig Light Chainâ€Specific Cytotoxic T Lymphocytes. <i>Clinical Cancer Research</i> , 2011, 17, 5945-5952.	7.0	9

#	ARTICLE	IF	CITATIONS
145	Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. <i>Nature Medicine</i> , 2011, 17, 983-988.	30.7	946
146	Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. <i>Blood</i> , 2011, 118, 2643-2643.	1.4	0
147	Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. <i>Stem Cell Research</i> , 2010, 5, 212-225.	0.7	26
148	Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.. <i>Blood</i> , 2010, 116, 2812-2812.	1.4	24
149	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	1.6	132
150	Phase II Study of Yttrium-90â€“Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5213-5218.	1.6	87
151	Vaccination strategies in follicular lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 189-195.	2.3	8
152	Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. <i>British Journal of Haematology</i> , 2009, 147, 515-525.	2.5	83
153	A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009, 114, 1714-1714.	1.4	7
154	Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.. <i>Blood</i> , 2009, 114, 465-465.	1.4	0
155	Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 831-836.	4.1	69
156	Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. <i>British Journal of Haematology</i> , 2008, 142, 179-191.	2.5	28
157	A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones. <i>Journal of Immunological Methods</i> , 2008, 331, 13-26.	1.4	15
158	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536.	1.4	294
159	Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 243-249.	2.5	9
160	BiovaxIDâ„¢: a personalized therapeutic cancer vaccine for non-Hodgkinâ€™s lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 113-122.	3.1	23
161	A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. <i>Clinical Cancer Research</i> , 2007, 13, 958-964.	7.0	150
162	A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. <i>Blood</i> , 2007, 109, 5407-5410.	1.4	18

#	ARTICLE	IF	CITATIONS
163	A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood, 2007, 109, 5160-5163.	1.4	33
164	Therapeutic Vaccine for Lymphoma. Yonsei Medical Journal, 2007, 48, 1.	2.2	7
165	Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).. Blood, 2007, 110, 2566-2566.	1.4	22
166	PD-1 Expression Is Markedly Upregulated on Intratumoral CD4+ and CD8+ T Cells in Follicular Lymphoma and Is Associated with T-Cell Exhaustion.. Blood, 2007, 110, 2749-2749.	1.4	10
167	Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Review of Vaccines, 2006, 5, 381-394.	4.4	18
168	Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. Journal of Controlled Release, 2006, 113, 261-270.	9.9	81
169	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 2005, 11, 986-991.	30.7	106
170	Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report. Clinical Lymphoma and Myeloma, 2005, 6, 61-64.	2.1	26
171	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen. Clinical Cancer Research, 2004, 10, 8309-8317.	7.0	75
172	A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. Journal of Translational Medicine, 2004, 2, 9.	4.4	36
173	Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood, 2004, 104, 1961-1969.	1.4	55
174	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposome Encapsulated Lymphoma Membrane Proteins.. Blood, 2004, 104, 749-749.	1.4	3
175	Idiotype vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica, 2002, 87, 989-1001.	3.5	51